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WT1 interacts with MAD2 and regulates
mitotic checkpoint function
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Tumour suppressors safeguard the fidelity of the mitotic checkpoint by transcriptional
regulation of genes that encode components of the mitotic checkpoint complex (MCC). Here
we report a new role for the tumour suppressor and transcription factor, WT1, in the mitotic
checkpoint. We show that WT1 regulates the MCC by directly interacting with the spindle
assembly checkpoint protein, MAD2. WT1 colocalizes with MAD2 during mitosis and
preferentially binds to the functionally active, closed-conformer, C-MAD2. Furthermore, WT1
associates with the MCC containing MAD2, BUBR1 and CDC20, resulting in prolonged
inhibition of the anaphase-promoting complex/cyclosome (APC/C) and delayed degradation
of its substrates SECURIN and CYCLIN B1. Strikingly, RNA interference-mediated depletion of
WT1 leads to enhanced turnover of SECURIN, decreased lag time to anaphase and defects in
chromosome segregation. Our findings identify WT1 as a regulator of the mitotic checkpoint
and chromosomal stability.
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T1 is a zinc finger transcription factor that can activate
or repress target genes that control cell growth and
development1–3. WT1 is subject to alternative splicing
in two regions: a 17-amino acid (aa) insertion within the central
region of the protein (17AA) and the insertion of 3 aa (Lys-
Thr-Ser) within the zinc finger region (KTS). WT1 is expressed in
several organs and tissues of the embryo and is particularly
important for the development of the urogenital system where it
functions as a tumour suppressor4,5. Recent findings suggest that
WT1 is a key regulator of mesenchyme to epithelial balance
during development, and is also required for the maintenance of
several adult tissues6. A considerable body of evidence suggests
that WT1 can also act as an oncogene7,8. WT1 is overexpressed in
several cancers, including leukemia, breast, ovary, bone, lung and
brain, and is a promising therapeutic target9,10.
The accuracy of cell division is monitored at several steps and
is initiated at the beginning of mitosis by the spindle assembly
checkpoint (SAC). The SAC components, which include MAD1,
MAD2, BUBR1 and BUB3, play key roles to ensure correct
attachment of chromosomes to the mitotic spindle and fidelity
of chromosomal segregation during cell division. Impaired
SAC function promotes aneuploidy and contributes to genomic
instabilities and tumorigenesis11–13. Indeed, a majority of human
tumours accumulate mutations that deregulate the expression of
proteins essential for mitotic checkpoint function14–16. This
results in missegregation of chromosomes during mitosis and
contributes to chromosome instability (CIN).
MAD2 adopts two native conformations, open (O-MAD2) and
closed (C-MAD2), and has the ability to self-dimerize. C-MAD2
is the functionally active form of MAD2, which engages in the
formation and maintenance of the checkpoint signal cascade17–20.
The presence of unattached kinetochores activates the SAC signal
in which the MAD2–MAD1 complex generates a diffusible
anaphase wait signal. This mitotic checkpoint complex (MCC)
composed of MAD2, BUBR1, CDC20 and BUB3 then inhibits
the anaphase-promoting complex/cyclosome (APC/C). The
ubiquitin ligase activity of APC/C is critical for the degradation
of SECURIN and CYCLIN B1, and eventual anaphase
entry12,21–25. Several lines of evidence suggest that human
tumours with CIN have misregulated expression of MAD2.
Studies in mice heterozygous for MAD2 showed increased
frequency towards aneuploidy26–28.
Here we show that WT1 associates with C-MAD2 during
mitosis and regulates the mitotic checkpoint function. We
demonstrate that through interaction with MAD2, WT1 inhibits
APC/C-mediated degradation of SECURIN and CYCLIN B1, and
that ablation of WT1 protein in cells that normally express WT1
leads to chromosomal-segregation defects and early anaphase
entry. Our results reveal a previously unknown role of WT1 in the
direct regulation of mitotic checkpoint function and genomic
stability via its interaction with MAD2.
Results
WT1 interacts with MAD2 during mitosis. A yeast two-hybrid
screen performed with a discrete region of mouse WT1 protein
(residues 245–297; that contains the 17AA) using a HeLa com-
plementary DNA library revealed MAD2 as a potential interac-
tion partner. A direct interaction between WT1 and MAD2 was
confirmed in vitro by glutathione S-transferase (GST)-pulldown
assay where recombinant full-length (FL) His-tagged MAD2
protein associated with GST-WT1 (245–297) but not with the
control GST beads (Fig. 1a). Furthermore, Flag-tagged FL human
WT1 protein was also found to interact with MAD2 in vitro
(Fig. 1b). Binding assays comparing GST-WT1þ 17AA
(residues 180–297) and GST-WT1 D17AA (lacking the 17AA)
revealed that the 17AA region of WT1 was dispensable for the
MAD2 interaction (Fig. 1c).
We next sought to determine whether MAD2 interacts with all
the four major isoforms of human WT1 in the cells. HeLa cells
(which do not express WT1) were transfected with a plasmid
driving expression of either green fluorescent protein (GFP),
GFP linked to FL WT1 ( / isoform, which does not contain
either the 17AA or KTS insertions) or FL GFP-tagged WT1
( /þ isoform, which lacks the 17AA but contains the KTS
insertion). Whole-cell extracts were prepared and MAD2
immunoprecipitates from the transfected cells were analysed by
immunoblotting with anti-WT1 antibodies, which confirmed
that both the  / and  /þ WT1 isoforms interact with
endogenous MAD2 (Fig. 1d). Similar interaction assays were
carried out with the other FL GFP-tagged WT1 isoforms, the
WT1 (þ /þ ) that contains both the 17AA and the KTS regions,
and WT1 (þ / ) that contains the 17AA but not the KTS
domain (Fig. 1e). The results showed that endogenous MAD2
could interact with all four major isoforms of WT1. We also
analysed a WT1 mutant derivative (R394X) that mimics those
found in Denys Drash syndrome (WT1  /DDS) and lacks an
intact DNA-binding domain. The results revealed a weaker
MAD2-binding efficiency of WT1  /DDS with respect to FL
WT1  / (Fig. 1f), suggesting that DNA binding might play a
role in bringing WT1 in close proximity to MAD2.
To determine the MAD2-binding domain of WT1, several
internal deletion mutants of GST-WT1 were generated (Fig. 2a,
schematic) and tested for their ability to interact with MAD2.
Deletion of the region between residues 280 and 295 (D3 and D4)
led to a significant reduction in the WT1-MAD2 interaction
(Fig. 2a). We therefore deleted the (D4) region spanning amino
acids 288–295 in the FL human GFP-WT1 / isoform and
tested whether this region of WT1 is crucial for MAD2
interaction in cells. The results showed significant reduction in
GFP-WT1 /D4 and MAD2 interaction when compared with
GFP-WT1 / (Fig. 2b).
We next performed co-immunofluorescence analysis in WiT49
cells (a Wilms’ tumour-derived cell line that expresses endogen-
ous wild-type WT1) with anti-MAD2 and anti-WT1 antibodies,
which revealed a significant co-localization pattern during the
pro-metaphase of mitosis (Fig. 2c). The centromeric localization
of MAD2 and WT1 was also studied using anti-CENPA
antibodies in our colocalization assays. MAD2 and CENPA were
juxtaposed close to the centromeres, while WT1 was localized
at the surrounding regions of the centromeres. To study the
association between endogenous WT1 and MAD2 during
activation of the checkpoint, co-immunoprecipitation analysis
was performed with whole-cell extracts prepared from nocoda-
zole-treated M15 cells (mouse mesonephric cell line), WiT49 cells
(human Wilms’ tumour cell line) and K562 cells (derived from
human chronic myelogenous leukemia). In each case, the
endogenous WT1 was present in MAD2 immunoprecipitates
(Fig. 2d). These results raised the possibility that the association
of WT1 with MAD2 might play a role in the regulation of SAC
function.
WT1 interacts with the active closed MAD2 conformer. MAD2
protein can adopt two native conformations: the closed
(C-MAD2) or the open (O-MAD2) conformers17–20. At the onset
of mitosis, O-MAD2 is recruited to the unattached kinetochores
of the pro-metaphase chromosomes with the help of its partner
MAD1, which catalyses the conversion of O-MAD2 to C-MAD2
conformer. The MAD1-C-MAD2 tetramer acts as a template for
additional O- to C-MAD2 conversion and initiates active SAC
signalling. CDC20 is a critical C-MAD2-binding partner, which
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occupies the same binding site on MAD2 as MAD1. Binding of
either MAD1 or CDC20 facilitates the formation of the C-MAD2
conformation29,30. A 12-aa MAD2-binding peptide (MBP1) has
been generated that competes for the same site on MAD2 that is
bound by MAD1 or CDC20. Comparative nuclear magnetic
resonance and co-crystal studies have revealed that the MAD2-
MBP1 complex adopts the C-MAD2 conformation, mimicking
MAD2 structure in either the MAD2–MAD1 or MAD2–CDC20
complexes18,29. We therefore employed MBP1 in our interaction
studies to test the binding preference of WT1 with the MAD2
conformers. Recombinant wild-type MAD2 protein equilibrates
between O- and C-MAD2 conformers and incubation of MAD2
with MBP1 shifts the equilibrium towards C-MAD2 conformer.
Pull-down assays were carried out with GST-WT1 (245–297)
and MAD2 that had been pre-incubated with either MBP1, or a
control peptide. The data revealed that GST-WT1 (245–297)
has a higher affinity for MAD2 that was pre-bound to MBP1 and
therefore for C-MAD2 (Fig. 3a).
Studies with several deletion and point mutants of MAD2 have
identified residues that are important for its dimerization and
also for acquiring the C/O-MAD2 state18,31. Deletion of 10 aa at
the carboxy terminus results in a MAD2 derivative that is locked
in the O-conformation and cannot bind MAD1, CDC20 or MBP1
(ref. 31). Similarly, when MAD2 lysine residue 13 is substituted
to alanine (L13A), it results in a MAD2 derivative locked in
C-conformation, while substitution of arginine residue 133 with
alanine (R133A) generates the monomeric form of MAD2, which
cannot self-dimerize. We generated a C-terminal 10 aa deletion
mutant of MAD2 (Del-C), C-MAD2 mutant (L13A) and MAD2
dimerization mutant, R133A and F141A, and then compared
their ability to interact with WT1 with respect to MBP1-bound
C-MAD2.
We performed pull-down assays with FL MAD2
(pre-incubated with MBP1 to generate C-MAD2) and MAD2
Del-C mutant (O-MAD2) in the presence of either Flag-M2 beads
or Flag-tagged FL WT1 protein. Interestingly, FL WT1 showed a
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Figure 1 | WT1 interacts with MAD2. (a) In vitro interaction assay was performed with either GST-WT1 (residues 245–297) or GST in the presence
of FL His-MAD2. The interaction was analysed by immunoblotting with anti-MAD2 antibody. Bound proteins were also resolved by SDS–PAGE and stained
with Coomassie Brilliant Blue. (b) In vitro pull-down assay was also performed with either Flag-M2 magnetic beads alone or incubated with FL Flag-tagged
WT1 protein in the presence of His-MAD2. The interaction was analysed by immunoblotting with anti-WT1 and anti-MAD2 antibodies. (c) GST interaction
assay was carried out with WT1 containing the 17 aa insertion (residues 180–297, þ 17AA) or lacking it (residues 180–297, D17AA) with His-MAD2.
The interaction was analysed by immunoblotting with anti-MAD2 antibody. Bound proteins were also resolved by SDS–PAGE and stained with Coomassie
Brilliant Blue. (d) HeLa cells were transfected with GFP Vector, FL GFP-WT1 ( / ) or GFP-WT1 ( /þ ) isoforms, and 48 h later whole-cell extracts
were prepared, followed by immunoprecipitation with anti-MAD2 antibodies. The immunoprecipitates were probed with anti-WT1 antibody. Blotting with
anti-MAD2 antibody was performed as a control. (e) The MAD2 interaction with ectopically expressed GFP-tagged FL WT1 (þ /þ ) and WT1 (þ / )
isoforms was analysed as in d (f) HeLa cells were transfected with pcDNA vector, pcDNA driving expression of WT1 /DDS (R394X) or wild-type
WT1 / , followed by immunoprecipitation with anti-MAD2 antibodies. The immunoprecipitates were probed with anti-WT1 antibodies. Blotting
with anti-MAD2 antibodies was performed as a control.
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greater level of binding to MAD2 that was pre-incubated with
MBP1, suggesting that WT1 has a higher affinity to interact with
C-MAD2 (Fig. 3b). Furthermore, GST-pull-down assays showed
that WT1 (residues 245–297) has higher affinity to interact with
C-MAD2 (L13A) when compared with MAD2 Del-C (Fig. 3c).
WT1 can also bind to O-MAD2 (Del-C), but at a lower affinity
than that observed for C-MAD2 that is induced by MBP1
(Fig. 3d). The different structural mutants of MAD2 (L13A,
R133A and F141A) were also found to efficiently interact with FL
Flag-WT1 (Fig. 3e). Taken together, these results suggest that
WT1 binds preferentially to C-MAD2 and that WT1 does
not bind to the same site in MAD2 as either MAD1 or CDC20.
To test whether WT1 can form a complex with MAD2 along
with other components of the MCC, we induced the spindle
checkpoint in K562 cells with nocodazole or taxol, prepared
whole-cell extracts and immunoprecipitated either MAD2 or
WT1 followed by immunoblotting with anti-BUBR1, MAD1,
CDC20, WT1 and MAD2 antibodies (Fig. 4a). Both anti-WT1
and anti-MAD2 antibodies co-immunoprecipitated MAD1,
CDC20 and BUBR1, suggesting that WT1 can associate with
17AA
250
WT1
Input
Input
GFP
IB: WT1
IB: MAD2
–/– –/–Δ4 –/– –/–Δ4 –/– –/–Δ4
WT1 GFP WT1 GFP WT1
Input
GST
IgG IgGMAD2 MAD2
M15 WiT49 K562
Input IgG MAD2 Input IgG MAD2
WT1
MAD2
DNA MAD2 WT1 Merge DNA merge
DNA MAD2 CENPA Merge DNA merge
DNA WT1 CENPA Merge DNA merge
GST
Δ1
Δ1
Δ2
Δ2
Δ3
Δ3
Δ 267 – 273
Δ 274 – 280
Δ 281 – 287
Δ 288 – 295Δ4
Δ4
266 267 297
kDa
kDa
25
76
25
kDa
52
25
IB: MAD2
IB: WT1
31
25
Figure 2 | Endogenous WT1 interacts with MAD2. (a) GST interaction assays were performed with the internal deletion mutants of GST-WT1
(schematic) with FL His-MAD2 and immunoblotted with anti-MAD2 and anti-GST antibodies. (b) Co-immunoprecipitation assays were carried out
with whole-cell extracts derived from HeLa cells that had been transfected with either GFP vector, GFP WT1 ( / ) or GFP-WT1 ( /D4) using
anti-MAD2 or anti-WT1 antibodies. (c) Co-immunofluorescence analysis was carried out in WiT49 cells with anti-MAD2 and anti-WT1 antibodies at
the pro-metaphase stage of mitosis. DNA was stained with Hoechst. Scale bar, 10mm. (d) M15, WiT49 and K562 cells were treated with 60ngml 1
nocodazole for 24 h, whole-cell extracts prepared and immunoprecipitation performed with anti-MAD2 antibodies followed by immunoblotting with
WT1 antibody. Input is 10% of the total whole-cell extract.
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Figure 3 | WT1 has higher affinity for the active closed MAD2 conformer. (a) GST interaction assays were carried out with WT1 (residues 245–297) and
FL His-MAD2 alone, and also with MAD2 pre-incubated with either 40 mM of MBP1, or a control peptide. The pull-down complexes were resolved by
SDS–PAGE and immunoblotted with anti-MAD2 antibodies. (b) In vitro pull-down assays were performed with either Flag-M2 magnetic beads alone or
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using anti-MAD2 and anti-WT1 antibodies. Input is 20% of the different MAD2 proteins used for interaction analysis.
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activated spindle/MCCs. The association of WT1 with the
MAD2–MAD1 complex is consistent with its localization during
the pro-metaphase stage (as seen in Fig. 2c). We therefore
determined the effect of MAD2 depletion on the subcellular
localization of WT1 during pro-metaphase. Co-immunofluores-
cence analysis of WT1 and MAD2 was performed in WiT49 cells
that had been transfected with MAD2 small interfering RNA
(siRNA), which resulted in the loss of WT1 localization pattern at
the chromosomes when compared with cells transfected with
control siRNA (Fig. 4b,c). Comparable effects were seen when we
performed a similar experiment in M15 cells (Supplementary
Fig. 1). However, RNA interference-mediated depletion of WT1
did not adversely affect the localization of MAD2 (Fig. 4b and
Supplementary Fig. 1). Taken together, these results show that
WT1 associates with the active C-MAD2 complex during mitosis,
suggesting a potential role in MAD2-dependent checkpoint
functions.
WT1 inhibits APC/C function. Our data so far suggest that
WT1 associates with C-MAD2 that forms part of the MCC. An
essential function of the MCC is to inhibit APC/C, an E3-ubi-
quitin ligase that marks SECURIN and CYCLIN B1 for degra-
dation, leading to chromosomal separation during anaphase. To
determine whether WT1 plays a role in the regulation of MAD2-
dependent APC/C inhibition, a ubiquitination/degradation assay
was performed with mitotic extracts prepared from nocodazole-
arrested HeLa cells (which do not express WT1), to which we
added either GST or GST-WT1, and incubated for different time
periods. The results showed that GST-WT1 significantly delayed
the degradation of SECURIN and CYCLIN B1 by APC/C com-
pared with GST (Fig. 5a). Immunoblotting with anti-MAD2,
GST and CDC27 (a subunit of APC/C) antibodies was performed
as controls. Quantitation of the levels of SECURIN and CYCLIN
B1 at the 45min time point are plotted as graphs (Fig. 5b).
The GST-WT1-D4 mutant (MAD2-interaction-defective mutant
lacking residues 288–295; see Fig. 2a) did not delay SECURIN and
CYCLIN B1 degradation, confirming that direct association with
MAD2 is essential for WT1-mediated APC/C inhibition (Fig. 5c).
To study the possible mechanism by which WT1 inhibits
APC/C activity, co-immunoprecipitation analysis was carried out
with whole cell extracts derived from WiT49 cells that had
been transfected with either control or WT1 siRNA followed by
treatment with dimethyl sulphoxide (DMSO) or nocodazole
(60 ngml 1). The results showed that on WT1 silencing the
association of MAD2 with MAD1 was significantly reduced in
both DMSO as well as nocodazole-treated cells (Fig. 5d),
suggesting a potential role of WT1 in promoting MAD2–
MAD1 interaction during the initiation of active checkpoint
signalling. Thus, WT1 integrates with and enhances the
formation of MAD2-containing spindle/MCCs, leading to a
sustained inhibition of APC/C activity. The results also show that
WT1 does not compete with MAD1 for MAD2 binding.
Presumably, WT1 may promote the stability of MAD1–MAD2
tetramer or recruit more O-MAD2 for amplifying the SAC signal.
Alternatively, WT1 could also induce or stabilize C-MAD2
conformation. Structural insights from MAD2-WT1 association
would reveal more information regarding the mode of action of
WT1 during checkpoint activation.
Depletion of WT1 promotes mitotic segregation defects. Our
results show that the interaction between WT1 and MAD2
enhances MCC function and leads to prolonged inhibition of
APC/C activity. This suggests that stimulation of SAC function by
WT1 could potentially affect chromosomal stability and genomic
integrity. To test this possibility, WiT49 cells were treated with
control siRNA, WT1 siRNA or MAD2 siRNA for 48 h, followed
by immunofluorescence analysis using anti-WT1 antibodies
(Fig. 6a). Depletion of WT1 protein resulted in an enhanced rate
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of chromosome lagging and bridges during anaphase, which was
strikingly similar to the defects observed on MAD2 silencing in
WiT49 cells (Fig. 6a, compare central two panels with lower
panel). Quantitation of lagging chromosomes in control and WT1
siRNA-transfected WiT49 cells is shown in Fig. 6b. Transfection
of M15 cells with WT1 siRNA also caused a significant increase in
lagging chromosomes (Fig. 6b). Consistent with these observa-
tions, siRNA-mediated knockdown of either WT1 or MAD2
resulted in faster degradation of SECURIN when compared
with control siRNA in WiT49 cells treated with either DMSO or
nocodazole (Fig. 6c).
Ablation of MAD2 protein results in defective SAC signalling.
As a consequence, cells exit mitosis without stringent monitoring
of kinetochore-spindle attachment errors. We scored the relative
mitotic indices for WiT49 cells transfected with control, MAD2
or WT1 siRNAs (Fig. 6d). The mitotic index was drastically
reduced on MAD2 silencing in nocodazole-treated cells. Knock-
down of WT1 also showed significant reduction in the number of
metaphase cells in nocodazole-treated cells when compared with
control. These results suggest that the absence of either MAD2 or
WT1 abrogates SAC function, leading to faster exit from mitosis
and accumulation of chromosome-segregation defects in the cells.
We also determined whether chromatin condensation during
mitosis was affected on MAD2 or WT1 silencing. Interestingly,
we observed a large reduction in the level of Histone H3 serine10
phosphorylation (H3S10p) in WiT49 and M15 cells transfected
with either MAD2 or WT1 siRNAs (Fig. 6e). However, the effect
of WT1 knockdown was not significant in MCF7 cells, suggesting
the possible role of other cell-type-specific components in the
regulation of WT1 functions during mitosis. Taken together, the
data in Fig. 6a–e suggest that loss of WT1 results in a hypo-active
SAC signalling and early anaphase entry, leading to an increase in
erroneous or incomplete spindle attachments to the kinetochores
and chromosome lagging during anaphase.
Discussion
WT1 is a transcription factor with diverse functions in the cell
ranging from organogenesis and tumour suppression to oncogen-
esis6–10,32. In this study we have uncovered a unique role for
WT1 as a mitotic checkpoint regulator. WT1 performs this
function without significantly affecting the expression of genes
crucial for SAC/MCC regulation. We also found that depletion of
MAD2 by siRNA does not influence transcription of WT1 target
genes (Fig. 6f). Several transcription factors are known to regulate
the mitotic checkpoint through control of the expression of SAC
and MCC components33. Our finding of a direct role for WT1 in
the MCC has demonstrated a novel mechanism of action for a
tumour suppressor/oncogene in the control of mitosis.
WT1 is aberrantly expressed in tumours of several different
origins7,9,10. Thus, a role in the regulation of APC/C activity
could potentially contribute to the misregulation of the mitotic
checkpoint in tumorigenesis. Conversely, loss of WT1 protein
could compromise the SAC function, and thereby contribute to
increased mitotic checkpoint failure and eventually CIN. Indeed,
loss of WT1 has also been associated with abnormal chromosome
number34,35. It would be of interest to study whether aberrant
WT1 expression contributes to aneuploidy in different cancers as
an outcome of its role in the regulation of cell cycle checkpoint.
There are several factors that modulate MAD2-dependent
checkpoint functions. p31 comet is a critical regulator of MAD2,
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which interacts with MAD1- or CDC20-bound MAD2 and
negatively regulates the SAC function. p31 comet binds to the
dimerization interface of MAD2 and promotes dissociation
of CDC20-MAD2 containing MCC36,37. Interestingly, WT1
influences MAD2 function in an opposite manner to p31 comet
and instead stabilizes MCC-mediated inhibition of APC/C and
positively regulates the SAC function. WT1 preferentially binds to
MBP1-bound MAD2, suggesting it favours the C-MAD2
conformer and does not compete with either MAD1 or CDC20
binding. Furthermore, knockdown of WT1 reduces MAD1–
MAD2 interaction in the cells, which indicate that WT1 is not a
competitive inhibitor of MAD1. Rather it augments MAD1–
MAD2 association crucial for active SAC signalling. This property
of WT1 is also different from the role played by Shugoshin
(human Sgo2), which competes with MAD1 and CDC20 for
binding to MAD2 during meiosis38. WT1 neither competes with
MAD2-dimerization interface nor the MAD1/CDC20-binding
site, yet significantly influences MAD2-dependent MCC
functions. The interplay among these cellular regulators of
MAD2 and their relative expression could therefore influence
the final timing of anaphase entry and stringency of chromosome
segregation. Our findings also raise the likelihood that other
tumour suppressors might also act on the MCC directly and
not only through the regulation of the abundance of MCC
components.
Methods
Cell culture and transfection. WiT49 (derived from human anaplastic Wilms’
tumour), HeLa (derived from human cervical carcinoma), MCF7 (derived from
human breast ductal carcinoma) and M15 (derived from developing mouse kidney)
cells were grown in DMEM, and K562 cells (derived from chronic myelogenous
leukemia) were grown in RPMI, supplemented with 10% (vol/vol) fetal bovine
serum at 37 C. Transfection of plasmids was performed using Effectene reagent
(Qiagen). Cells were harvested 48 h after transfection and processed for different
assays. The human and mouse MAD2 siRNAs and mouse WT1 siRNA were
obtained from Qiagen. Human WT1 siRNA was obtained from Ambion.
siRNAs were transfected using Hiperfect reagent (Qiagen) for 48 h.
Plasmid constructs and protein purification. FL human MAD2 was cloned from
HeLa cDNA library in PRSET-A His-tagged vector. Point and deletion mutants
were generated using a site-directed mutagenesis kit (Agilent). GST, GST-WT1
(and deletion mutants) were expressed in BL21-DE3 competent cells, and
His-tagged human MAD2 (and mutant derivatives) were expressed in BL21-
DE3(pLysS) competent cells followed by affinity purification as described before39.
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Flag-tagged FL WT1 protein (residue 1–449, including exon 5/17AA and KTS) was
purchased from Creative Biomart. The MBP1 was purchased from Peptide 2.0
(sequence: SWYSYPPPQRAV); Control peptide sequence: CKATKDPSRVGDS.
GFP-tagged FL isoforms WT1 ( / ) and WT1 ( /þ ) were kind gifts
from Professor Brigitte Royer-Pokora. GFP-tagged FL isoform WT1 (þ /þ )
was purchased from GeneCopoeia Inc., and GFP WT1 (þ / ) was generated
by deleting the KTS region using site-directed mutagenesis kit (Agilent).
RNA analysis. Total RNA was prepared using the QIAGEN RNeasy kit and cDNA
was prepared using the BioRad iScript cDNA synthesis kit. Real-time PCR was
performed using a BioRad MiniOpticon System and BioRAd SYBR Green assay
reagents. Primers used in the analysis were: MAD2, Fwd: 50-ACGGTGACATTTC
TGCCACT-30 , Rev: 50-TGGTCCCGACTCTTCCCATT-30 ; WT1, Fwd: 50-CCGCT
ATTCGCAATCAGGGT-30 , Rev: 50-ACTTGTTTTACCTGTATGAGTCCTG-30 ;
AREG, Fwd: 50-TGGATTGGACCTCAATGACA-30 , Rev: 50-ACTGTGGTCCCCA
GAAAATG-30; EREG, Fwd: 50-GCTCTGCCTGGGTTTCCATC-30 , Rev: 50-CC
ACACGTGGATTGTCTTCTGTC-30; CYCLIN E, Fwd: 50-CTCCAGGAAGAGGA
AGGCAA-30 , Rev: 50-TCGATTTTGGCCATTTCTTCA-30 ; GAPDH, Fwd: 50-ACA
GTCAGCCGCATCTTCTT-30 , Rev: 50-ACGACCAAATCCGTTGACTC-30 .
Western blotting and immunofluorescence analysis. Western blotting analysis
was performed as described before40. In brief, cells were incubated with non-
denaturing lysis buffer (20mM Tris HCl pH 8, 150mM NaCl, 1% (v/v) NP-40,
2mM EDTA) for 30min and prepared for western blotting. Whole-cell lysates
were electrophoresed and transferred to polyvinylidene difluoride membrane
(Millipore). The membranes were blocked in PBS, 0.1% (v/v) Tween 20 and 5%
(w/v) milk for 1 h at room temperature followed by incubation with primary
antibodies (1:1,000 dilution) prepared in PBS, 0.1% (v/v) Tween 20 and 2.5% milk
for 12 h at 4 C. Membranes were then washed three times with PBS and incubated
for 3 h with a horseradish peroxidase-conjugated anti-rabbit, anti-mouse or
anti-goat IgG secondary antibody (1:5,000 dilution, Jackson ImmunoResearch).
Membranes were washed three times with PBS and proteins were detected using
ECL Western blotting detection kit (Amersham). Uncropped scans of western
blottings are provided in Supplementary Figs 2–7.
Immunofluorescence analysis was performed as previously described41. Briefly,
cells were grown on coverslips and were washed with PBS followed by cross-linking
in 4% (v/v) paraformaldehyde in PBS for 15min at room temperature. The cells
were washed once in PBS and incubated in blocking solution for 30min at room
temperature. The cells were then incubated in PBS containing primary antibody
(1:100 dilution) for 1 h and washed twice with PBS followed by incubation in
DyLight 488- or DyLight 549-conjugated goat anti-rabbit/anti-mouse IgG
secondary antibodies (1:500 dilution, Thermo Scientific) for 1 h. DNA was
stained with Hoechst dye and the cells were mounted using Fluoromount-G
(Southern Biotech). The immunofluorescence signal was visualized using Zeiss
LSM 710 Confocal Microscope.
The following antibodies were used for western blotting and
immunofluorescence analysis: MAD2 (C-19-sc-6329, FL-205-sc-28261), CDC20
(sc-1907), CYCLIN B1 (sc-245), WT1-F6 (sc-7385) and WT1-C-19 obtained from
Santa Cruz Biotechnology. MAD2 (A300-301A), MAD1 (A300-339A), BUBR1
(A300-386A), and CDC27 (A301-184A) antibodies were obtained from Bethyl
Laboratories. SECURIN (ab3305), H3S10p (ab5176), H3 (ab1791), CENPA
(ab13939) and b-TUBULIN (ab6046) antibodies were obtained from Abcam.
APC/C-ubiquitination activity assay. The APC/C-ubiquitination activity assay
was performed as described before20. HeLa cells were blocked in prometaphase
stage by treatment with 2.5mM thymidine for 24 h, followed by treatment with
60 ngml 1 nocodazole for 12 h. Nocodazole-arrested HeLa cells were washed
with ice-cold PBS and resuspended in 75% of pellet volume of hypotonic buffer
(20mM Hepes-NaOH, pH 7.6, 5mM KCl, 1mM dithiothreitol) containing
protease inhibitor cocktail (Roche). After repeated freeze-thawing on dry ice,
the cell lysates were centrifuged at 13,000 r.p.m. for 1 h. The supernatant was
supplemented with glycerol to 10% (v/v) and used in APC/C activity assay.
Twenty-microlitre reaction mixtures contained 10 ml of concentrated mitotic
extract (B 10mgml 1), 2 ml of 10 degradation mixture (100mM Tris–HCl,
pH 7.6, 50mM MgCl2, 10mM dithiothreitol, 10mgml 1 ubiquitin, 100mM
phosphocreatine, 5mM ATP, 0.1mgml 1 UbcH10) and 1 ml of 20 creatine
phosphokinase (1mgml 1) (Sigma). Reactions were incubated at 30 C in the
presence of different recombinant proteins, and 3-ml samples were withdrawn at
indicated time points in SDS–PAGE sample buffer. Degradation of CYCLIN B
and SECURIN was followed by western blotting.
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